Molecubes Preclinical SPECT Imager
Medicines Discovery Catapult Limited
This goods contract from Medicines Discovery Catapult Limited is closed to new bids. It was awarded to SOUTHERN SCIENTIFIC LIMITED for £350,000 on 17 Sept 2025. The contract end date is 2 Jan 2027. Region: North West. Procedure: Direct award.
Contracts like this usually come back out to tender before they end.
Live now: tenders like this
- NU2251 High Resolution Maskless LithographyNewcastle University£613,350 · Closes 27 November 2026
- CSAC2334 Thermal Interface Material (TiM) reliability testerSemiconductor Catapult£100,000 · Closes 2 December 2026
- CEFAS26-118 Laser Diffraction Particle Size and Image Particle Shape AnalyserCentre For Environment, Fisheries And Aquaculture Science£66,667 · Closes 7 December 2026
- Laser Powder Bed Fusion (LPBF) System (3D Printer)Nottingham Trent University£166,667 · Closes 9 December 2026
- Advanced Textile Performance Testing and Sustainability Evaluation PlatformThe University of ManchesterCloses 11 December 2026
Get tenders like this by email
New tenders like this one, in your inbox every morning. Starts with 14 days of Pro, no card needed.
Unsubscribe in one click. See our privacy policy.
Key details
Procurement
Description
MDC's current imaging capabilities are limited to PET and CT, which restricts us to PET based tracers. While PET imaging is a powerful tool, it cannot accommodate a growing range of radioisotopes that are increasingly relevant in theranostic applications.
These include lead 203, lead 212, lutetium 177, and actinium 225, which are essential for both diagnostic and therapeutic purposes. This limitation has become more pronounced as clinical and research interest in SPECT and CT imaging continues to grow.
SPECT imaging enables biodistribution studies for isotopes that PET cannot support. This opens up new possibilities for molecular imaging and expands our ability to respond to evolving scientific and clinical needs. We have a clear opportunity to address this gap by introducing SPECT and CT capability through the phased procurement of the SPECT Cube module, followed by an upgrade to the advanced SPECT Cube 2.0 platform. This will allow MDC to meet rising diagnostic demand, align with industry standards, and maintain clinical competitiveness.
The system supports high-energy collimators and emerging radionuclides such as 212-Pb and 203-Pb, which are critical for MDC's research pipeline and are the only system compatible with existing MDC Molecubes equipment which enables an integrated system allowing simultaneous imaging of SPECT PET and CT imaging in one work flow.
Awarded supplier
Contact
Identifiers
Explore related tenders
External ID: fts-ocds-h6vhtk-059ecc • Added 6 August 2026